|Neurology Clinical Programs||
A Phase 2/3, Multi-Center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing Multiple Sclerosis patients.
Patients will have a 67% (2 out of 3) chance of being assigned to one of the active doses of RPC1063 and 33% (1 out of 3) chance of being assigned to Avonex®.
In addition, because this study is double blinded, you will also be “treated” with a placebo. A placebo is one that contains no active substance but may resemble a real medication. Since Avonex® is administered by injection, and RPC1063 is administered orally (capsule), patients enrolled in this study will be required to receive both types of delivery (orally and injection) so that no one will be able to tell which active medication the patient is truly being given. This study is completely blinded, meaning, you, your doctor, and the Sponsor, Receptos, Inc. will not know if you‟re getting RPC1063 or Avonex® until the entire study is concluded for all subjects.
Participation in this study will last for approximately 28 months and include a 2 year treatment period.
If you have been diagnosed with a relapsing form of MS, are between the ages of 18-55, have not been treated with natalizumab, fingolimod or other SIP1R agonists and are able to come to UCSF for study visits you may be eligible to participate.